Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric …

T André, D Tougeron, G Piessen… - Journal of Clinical …, 2023 - univ-rennes.hal.science
PURPOSE: In patients with resectable gastric/gastroesophageal junction (GEJ)
adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard …

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric …

T André, D Tougeron, G Piessen… - Journal of Clinical …, 2023 - hal.sorbonne-universite.fr
PURPOSE: In patients with resectable gastric/gastroesophageal junction (GEJ)
adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard …

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric …

T André, D Tougeron, G Piessen… - Journal of Clinical …, 2023 - hal-emse.ccsd.cnrs.fr
PURPOSE: In patients with resectable gastric/gastroesophageal junction (GEJ)
adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard …
[PDF] hal.science

[PDF][PDF] Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or …

T André, D Tougeron, G Piessen, C de La… - J Clin Oncol, 2022 - hal.science
RESULTS Between October 2019 and June 2021, 32 patients with dMMR/MSI-H
gastric/GEJ adenocarcinoma were enrolled. The median age was 65.5 years (range, 40-80) …

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric …

T André, D Tougeron, G Piessen… - 2023 - lilloa.univ-lille.fr
PURPOSEIn patients with resectable gastric/gastroesophageal junction (GEJ)
adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard …

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric …

T André, D Tougeron, G Piessen… - Journal of Clinical …, 2023 - hal.umontpellier.fr
PURPOSE: In patients with resectable gastric/gastroesophageal junction (GEJ)
adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard …